GSK Wants USPTO Appeals Board Ruling Overturned
The U.S. Board of Patent Appeals and Interferences has erroneously invalidated claims for several inhaler patents in favor of Novartis Corp., according to a complaint filed by Glaxo Group Ltd. and...To view the full article, register now.
Already a subscriber? Click here to view full article